1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML

1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML

308435

1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML

One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare brain infection — called progressive multifocal leukoencephalopathy (PML) — in people with multiple sclerosis (MS), a study suggests. The study, “Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment,” was published in the journal Viruses. MS therapies are designed to suppress the immune system and limit the inflammatory damage to the myelin sheath that…

You must be logged in to read/download the full post.